APA (7th ed.) Citation

P, S., DSW, T., M, M., M, O., J, S., RD, C., . . . DS, H. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for immunotherapy of cancer, 10(2), . https://doi.org/10.1136/jitc-2021-003776

Chicago Style (17th ed.) Citation

P, Schöffski, et al. "Phase I/II Study of the LAG-3 Inhibitor Ieramilimab (LAG525) ± Anti-PD-1 Spartalizumab (PDR001) in Patients with Advanced Malignancies." Journal for Immunotherapy of Cancer 10, no. 2 (2022). https://doi.org/10.1136/jitc-2021-003776.

MLA (9th ed.) Citation

P, Schöffski, et al. "Phase I/II Study of the LAG-3 Inhibitor Ieramilimab (LAG525) ± Anti-PD-1 Spartalizumab (PDR001) in Patients with Advanced Malignancies." Journal for Immunotherapy of Cancer, vol. 10, no. 2, 2022, https://doi.org/10.1136/jitc-2021-003776.